Prothena Corporation plc (NASDAQ:PRTA – Free Report) – Equities research analysts at HC Wainwright increased their FY2026 earnings per share estimates for shares of Prothena in a research report issued to clients and investors on Friday, August 7th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will earn ($0.47) per share for the year, up from their prior estimate of ($0.63). HC Wainwright has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for Prothena’s current full-year earnings is $0.18 per share. HC Wainwright also issued estimates for Prothena’s FY2027 earnings at ($1.28) EPS, FY2028 earnings at $1.10 EPS, FY2029 earnings at ($1.25) EPS and FY2030 earnings at $2.37 EPS.
Prothena (NASDAQ:PRTA – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.07. Prothena had a negative return on equity of 16.45% and a negative net margin of 80.68%.The business had revenue of $1.01 million during the quarter, compared to the consensus estimate of $0.42 million.
View Our Latest Research Report on PRTA
Prothena Stock Up 4.1%
NASDAQ:PRTA opened at $9.12 on Tuesday. Prothena has a twelve month low of $7.39 and a twelve month high of $11.80. The business has a 50 day moving average price of $8.89 and a two-hundred day moving average price of $9.40. The company has a market cap of $477.43 million, a P/E ratio of -10.86, a price-to-earnings-growth ratio of 1.40 and a beta of -0.29.
Insider Activity at Prothena
In related news, General Counsel Michael John Isaacs sold 8,386 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $8.47, for a total transaction of $71,029.42. Following the transaction, the general counsel directly owned 35,745 shares of the company’s stock, valued at approximately $302,760.15. This trade represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Anne Evans Kingston sold 7,662 shares of the business’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $8.47, for a total transaction of $64,897.14. Following the completion of the sale, the insider directly owned 55,782 shares of the company’s stock, valued at $472,473.54. This represents a 12.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have acquired 345,000 shares of company stock worth $3,097,250. Corporate insiders own 10.40% of the company’s stock.
Institutional Trading of Prothena
A number of institutional investors and hedge funds have recently made changes to their positions in PRTA. Jacobs Levy Equity Management Inc. bought a new position in Prothena in the first quarter valued at approximately $230,000. Creative Planning lifted its position in shares of Prothena by 373.0% during the 2nd quarter. Creative Planning now owns 50,569 shares of the biotechnology company’s stock worth $307,000 after buying an additional 39,879 shares during the last quarter. American Century Companies Inc. grew its position in Prothena by 72.1% in the second quarter. American Century Companies Inc. now owns 59,965 shares of the biotechnology company’s stock valued at $364,000 after acquiring an additional 25,129 shares during the last quarter. Russell Investments Group Ltd. raised its stake in Prothena by 7,956.6% during the second quarter. Russell Investments Group Ltd. now owns 96,196 shares of the biotechnology company’s stock worth $584,000 after acquiring an additional 95,002 shares in the last quarter. Finally, Hsbc Holdings PLC lifted its holdings in shares of Prothena by 251.8% in the second quarter. Hsbc Holdings PLC now owns 46,047 shares of the biotechnology company’s stock worth $282,000 after acquiring an additional 32,959 shares during the last quarter. Institutional investors own 97.08% of the company’s stock.
Prothena Company Profile
Prothena Corporation plc is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for neurodegenerative and rare diseases driven by misfolded proteins. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates. Prothena leverages proprietary protein engineering and antibody discovery platforms to advance candidates through preclinical and clinical stages.
The company’s most advanced program is an antibody targeting aggregated alpha-synuclein for the potential treatment of Parkinson’s disease, currently in mid-stage clinical trials.
Featured Stories
- Five stocks we like better than Prothena
- 3 Overlooked Stocks Analysts Still Like as AI Trades Get Crowded
- China’s Athleisure Boom Is Not Lifting Every Brand Equally
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.
